CytoMed Therapeutics Reports 1H 2023 Financial Report And Provides Corporate Update; Cash And Cash Equivalents: As Of June 30, 2023, The Company Had Cash And Cash Equivalents Of $7.72M
CytoMed Therapeutics Reports 1H 2023 Financial Report And Provides Corporate Update; Cash And Cash Equivalents: As Of June 30, 2023, The Company Had Cash And Cash Equivalents Of $7.72M
Financial Results for the Six Months Ended June 30, 2023
截至2023年6月30日的六个月财务业绩
Net Loss: For the six months ended June 30, 2023, the Company's unaudited net loss amounted to S$1.16M ($860,695) excluding expenses related to its NASDAQ Initial Public Offering (IPO) in April 2023 and the costs associated with being a public listed company, compared to S$936,377 for the six months ended 2022.
净亏损：在截至2023年6月30日的六个月中，公司未经审计的净亏损为116万新元（合860,695美元），其中不包括与2023年4月纳斯达克首次公开募股（IPO）相关的费用以及与上市公司相关的成本，而截至2022年的六个月中，净亏损为936,377新元。
Cash and Cash Equivalents: As of June 30, 2023, the Company had cash and cash equivalents of S$10.44M ($7.72M). Over the course of the last six months, the Company raised S$12.94M ($9.57M) gross proceeds from the IPO.
现金及现金等价物：截至2023年6月30日，该公司的现金及现金等价物为1044万新元（合772万美元）。在过去的六个月中，该公司从首次公开募股中筹集了1294万新元（合957万美元）的总收益。
R&D Expenses: The Company's research and development expenses were S$811,319 ($599,955) and S$604,043 for the six months ended June 30, 2023, and 2022, respectively. This was primarily due to the clinical progress achieved over the last six months.
研发费用：截至2023年6月30日和2022年6月30日的六个月，该公司的研发费用分别为811,319新元（合599,955美元）和604,043新元。这主要是由于在过去六个月中取得的临床进展。
G&A Expenses: The Company's general and administrative expenses were S$1.50M ($1.11M) and S$306,457 for the six months ended June 30, 2023, and 2022, respectively. The increase was primarily driven by non-recurring IPO expenses and the costs associated with being a public listed company.
并购费用：截至2023年6月30日和2022年6月30日的六个月，公司的一般和管理费用分别为150万新元（合111万美元）和306,457新元。增长主要是由非经常性IPO支出以及与上市公司相关的成本推动的。
译文内容由第三方软件翻译。